Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Intellectual Property Protection: Foreign Governments Get To Argue Their Case To USTR Before Publication Of "Watch Lists"

Executive Summary

For the first time, the U.S. Trade Representative is giving foreign governments and others a chance to publicly testify before issuing its 2010 Special 301 report on countries it deems do not provide adequate protection of intellectual property rights

You may also be interested in...



Canada Patent Protections In Spotlight As PhRMA Seeks Addition To “Priority Watch List”

The drug industry sees a not-so-friendly neighbor to the North and wants help from the Office of the U.S. Trade Representative to get Canada to change its “promise utility doctrine.”

Global IP Protection: Data Exclusivity Is Top USTR Concern As Licensing Recedes

The U.S. Trade Representative's most recent report on global intellectual property rights suggests compulsory licensing may be receding somewhat as a worry for pharmaceutical companies, but inadequate data protection remains a strong concern

Global IP Protection: Data Exclusivity Is Top USTR Concern As Licensing Recedes

The U.S. Trade Representative's most recent report on global intellectual property rights suggests compulsory licensing may be receding somewhat as a worry for pharmaceutical companies, but inadequate data protection remains a strong concern

Topics

Latest Headlines
See All
UsernamePublicRestriction

Register

PS051869

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel